Opinion
Video
Unveiling Cardiovascular Disparities in Lp(a)
Michael D. Shapiro, DO, and Jaime Murillo, MD, discuss the implications of high Lp(a) levels in the US population, racial disparities, and tailored interventions for high-risk groups.
This is a video synopsis/summary of an Insights involving Michael D. Shapiro, DO, and Jaime Murillo, MD.
Shapiro highlights findings from the US subgroup analysis of the global heritage study, emphasizing a notably high prevalence of elevated lipoprotein(a) (Lp[a]) levels among individuals with atherosclerotic cardiovascular disease (ASCVD). He stresses the relevance of measuring Lp(a) even in established ASCVD cases, as elevated Lp(a) provides additional risk information beyond standard cardiovascular factors, enabling more intensive low-density lipoprotein cholesterol lowering and prevention strategies.
Shapiro further addresses racial disparities, particularly among Black individuals, with half exhibiting elevated Lp(a) levels. This disparity increases Lp(a) attributable risk significantly, emphasizing the necessity of routine Lp(a) screening for both established ASCVD and at-risk individuals within this demographic. Additionally, Murillo emphasizes the impact on population health, especially among minority groups experiencing a surge in cardiovascular deaths, highlighting the need for targeted interventions.
Murillo stresses the importance of community engagement and partnership with scientists to address historical mistrust, advocating for comprehensive interventions targeting traditional risk factors and lifestyle modifications. This approach extends beyond Lp(a) measurement, focusing on holistic risk management within high-risk communities. These insights underscore the urgency of tailored interventions and routine Lp(a) screening to address disparities and mitigate cardiovascular risks among disproportionately affected populations.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
